Smart drug delivery technologies for Inflammatory Bowel Diseases (IBD) focus on site-specific therapeutic delivery, enhancing treatment efficacy while minimizing side effects. Recent advancements, including ingestible smart capsules, offer precise targeting within the gastrointestinal (GI) tract. Despite previous commercialization challenges, progress in technology, miniaturization, and component design has reignited interest. Smart capsules, equipped with drug reservoirs, sensors, and localization mechanisms, promise improved treatment for IBD by accurately releasing drugs at disease sites, overcoming limitations of traditional drug delivery methods.
Trending
- GI 2.0: The Playbook | Industry Perspectives
- Disorders of Gut–Brain Interaction and the Rome V Process (Gastroenterology)
- Physician triage changed management in nearly 1 in 4 GI referrals (GI & Hepatology News)
- Upper GI Disorders: New Evidence May Refine Clinical Practice (Medscape)
- Pennsylvania Sues Chatbot Over Claims It Impersonates Doctors (MedCity News)
- Physician independence vanishes as corporate medicine swallows up U.S. health care (Medical Economics)
- Oshi Health Appoints Danny Krifcher as President and Chief Operating Officer (PR Newswire)
- Better onboarding may help GI practices retain APPs (GI & Hepatology News)
